Document is current
Any future updates will be listed below
-
Authors
Dima, Danai https://orcid.org/0000-0002-3587-7975
Abdallah, Al-Ola
Davis, James A. https://orcid.org/0000-0001-7978-1652
Awada, Hussein https://orcid.org/0000-0002-1445-7947
Goel, Utkarsh
Rashid, Aliya
DeJarnette, Shaun
Anwer, Faiz https://orcid.org/0000-0001-6914-7439
Shune, Leyla
Raza, Shahzad https://orcid.org/0000-0002-2739-2265
Mahmoudjafari, Zahra https://orcid.org/0000-0002-3168-2521
Williams, Louis
Faiman, Beth
McGuirk, Joseph P. https://orcid.org/0000-0002-0539-4796
Sauter, Craig S.
Ahmed, Nausheen https://orcid.org/0000-0003-4336-4982
Khouri, Jack
Hashmi, Hamza https://orcid.org/0000-0002-4129-5867
- License Information
-
More Information
Article History
Received: 27 February 2024
Revised: 1 May 2024
Accepted: 9 May 2024
First Online: 31 May 2024
Competing interests
: Faiz Anwer: Research Funding and Consultancy for BMS, Janssen, Allogene Therapeutics. Hamza Hashmi: Consultancy for Janssen, Karyopharm, GSK, Sanofi, and Bristol-Myers Squibb (BMS). Jack Khouri: Consultancy for Janssen. Nausheen Ahmed: Advisory board for BMS; Consultancy for Gilead and Kite Pharma. Shahzad Raza: Advisory board for Kite Pharma, Pfizer and Prothena biosciences. Louis Williams: Consulting for BMS, Janssen, Abbvie. Craig S. Sauter: Consultancy for Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK; Research Funding for Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. The remaining authors declare no competing interests.
: This study was IRB approved and was conducted under the Declaration of Helsinki.
